<DOC>
	<DOCNO>NCT00080795</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide , doxorubicin , gemcitabine , cisplatin , work different way stop tumor cell divide stop grow die . Combining one drug , give surgery , may shrink tumor remove . PURPOSE : This phase II trial study well neoadjuvant combination chemotherapy work treat patient undergo radical cystectomy locally advance carcinoma urothelium .</brief_summary>
	<brief_title>Neoadjuvant Ifosfamide , Doxorubicin , Gemcitabine , Cisplatin Treating Patients Who Are Undergoing Radical Cystectomy Locally Advanced Carcinoma ( Cancer ) Urothelium</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate 4-year disease-free survival patient locally advance carcinoma urothelium undergo radical cystectomy treat neoadjuvant chemotherapy comprise ifosfamide , doxorubicin , gemcitabine follow cisplatin , gemcitabine , ifosfamide . Secondary - Compare perioperative morbidity mortality patient treat regimen vs historical standard . OUTLINE : Patients receive neoadjuvant chemotherapy comprise ifosfamide IV 3 hour day 1-4 , doxorubicin IV day 3 , gemcitabine IV 30 minute day 2 4 , filgrastim ( G-CSF ) subcutaneously day 7-12 blood count recover . Treatment repeat every 3 week total 3 course . Patients receive cisplatin IV , gemcitabine IV 90 minute , ifosfamide IV 30 minute day 1 . Treatment repeat every 2 week total 4-6 course . Four six week completion neoadjuvant chemotherapy , patient undergo cystectomy . Patients follow 9 , 12 , 15 , 18 , 24 , 30 month annually thereafter . PROJECTED ACCRUAL : A total 31-49 patient accrue study within 16-25 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm carcinoma urothelium , meet 1 follow criterion locally advanced disease : Clinical stage T3b disease , define presence mass examination anesthesia Clinical stage T4a disease , define direct invasion prostatic stroma , vagina , rectum Lymphovascular invasion transurethral resection specimen Upper tract disease micropapillary histology allow No evidence disease outside pelvis PATIENT CHARACTERISTICS : Age Any age Performance status 02 Life expectancy Not specify Hematopoietic Bone marrow function adequate Hepatic Liver function adequate Renal Creatinine clearance ≥ 45 mL/min Cardiovascular Ejection fraction ≥ 50 % Other Not pregnant No malignancy likely lifethreatening within next 4 year PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>